RCS - Fusion Antibodies - Patent application

Fusion AntibodiesAnnouncement

21/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230321:nRSU5717Ta&default-theme=true

RNS Number : 5717T  Fusion Antibodies PLC  21 March 2023

REACH

 

21 March 2023

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Patent application

 

Fusion Antibodies plc (AIM: FAB), a contract research organisation ("CRO")
providing discovery, design, and optimisation services for therapeutic
antibodies to the global healthcare market, announces that it has filed a
patent application for a panel of antibodies that bind to an important target
for cancer therapeutics. These antibodies have the potential to inhibit the
pro-tumourigenic activity of their target in cancer, which is supported by
pre-clinical data. The Company is exploring options to out-licence these
antibodies to a clinical development company to progress them into Phase I
clinical trials.

 

Dr Adrian Kinkaid, CEO of Fusion, commented: "We have a dedicated team of
scientists who continue to work on antibody discovery and expression, and we
remain confident in our ability to grow and create opportunities in this
field. We look forward to being able to update the market further, whilst also
growing our patent portfolio."

 

Enquiries:

 

 Fusion Antibodies plc                                  www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                Via Walbrook PR

 James Fair, Chief Financial Officer

 Allenby Capital Limited                                Tel: +44 (0)20 3328 5656
 James Reeve / Vivek Bhardwaj (Corporate Finance)

 Tony Quirke (Sales and Corporate Broking)

 Walbrook PR                Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                            Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the discovery and development of
antibodies for both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody design,
generation, development, production, characterisation and optimisation. These
services include antigen expression, antibody production, purification and
sequencing, antibody humanisation using Fusion's proprietary
CDRx (TM) platform and the production of antibody generating stable cell
lines to provide material for use in clinical trials. Since 2012, the Company
has successfully sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects and has an international, blue-chip
client base, which has included eight of the top 10 global pharmaceutical
companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

The global monoclonal antibody therapeutics market was valued at $135.4
billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase
at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the
world's ten top selling drugs were antibody-based therapeutics with the
combined annual sales of these drugs exceeding $63.2 billion.

 

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases into the public
domain.  Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be disseminated
as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQBLFLXXLLBBD